BevacizumabIt is monoclonal antibody which attaches to a protein called vascular endothelial growth factor (VEGF), required by the body grow blood vessels. It is thought that by doing this, the drug stops tumors from being able to create new blood vessels to feed the tumor. This limits the tumors supply of nutrients, which in turn may slow or stop their growth.
Metastatic colorectal cancer, Advanced nonosquamous non-small cell lung cancer, Metastatic kidney cancer, Breast cancer, Glioblastoma.
Intravenous infusion; 5-15mg/kg variable dose.
Paediatric: Safety not established. Pregnancy: Category C; Use if risk to fetus outweighs benefits. Lactation: Secreted in milk. Elderly: Increased side effects in elderly.
Nosebleeds, headache, high blood pressure, inflammation of the nose, taste change, dry skin, rectal bleeding, tear production disorder, back pain, inflammation of the skin, gastrointestinal (GI) perforation , serious bleeding, impair wound healing, stroke, vision problem, infusion reaction, infertility in women.